ECG Everus Construction (ECG) Insider Trading, Ownership & Congress Trades
Construction · Operative builders · CIK 0002015845
Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
268
13F, latest reported quarter
What the filings say about ECG
Insiders, 180 days
-$306.1K net sold
1 buyer · 1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$451.1K
1 notice
Everus Construction insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Everus Construction Group, Inc. insiders sold a net $306.1K of stock across 6 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 5.1% of the 19,658 shares held after it.
- No other insider bought within 30 days.
- 268 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SPARBY DAVID M bought about $144.9K of ECG on Aug 17, 2026, the largest insider purchase at the company on our record; 268 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 17.4% of the 18,950 shares held after it.
- No other insider sold within 30 days.
- 268 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, CLO & Corporate Secretary Sanderson Paul R. sold about $451.1K of ECG on Aug 7, 2026, the largest insider sale at the company on our record; 268 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 11.8% of the 2,110 shares held after it.
- No other insider bought within 30 days.
- 268 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hernandez Helena Mercedes bought about $23.0K of ECG on Dec 8, 2025; 268 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 23.6% of the 5,508 shares held after it.
- 2 other insiders bought within 30 days.
- 268 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, CFO & Treasurer Marcy Maximillian J bought about $50.7K of ECG on Feb 25, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 268 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 9.4% of the 14,928 shares held after it.
- 2 other insiders bought within 30 days.
- 268 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Ryan Edward A bought about $53.2K of ECG on Feb 25, 2025, the largest insider purchase at the company on our record; 2 other insiders bought within 30 days and 268 funds added in the latest 13F quarter.6 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$306.1K over 180 days
-$306.1K over 90 days
more than 65% of Construction
Congress
no House purchase disclosed in the last 12 months
Funds
268 funds bought in last quarter
more than 81% of Construction
Revenue
+31.5% year over year
more than 83% of Construction
Margin
5.4% net margin
more than 70% of Construction
Buybacks
no share repurchases reported
Short interest
4.0% of the float short (float per yahoo 2026-10-26) · 5.1 days to cover · settled 2026-09-30
more than 56% of Construction
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ECG
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+12.2%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ECG: institutional holders (13F)
13F holdings, latest reported quarter
6,593,812 sh
$1.1B
2,638,646 sh
$437.9M
2,304,744 sh
$382.5M
1,693,806 sh
$281.1M
1,569,546 sh
$260.5M
Congress trades in ECG
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ECG planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Sanderson Paul R.
Filed 2026-08-07
$451.1K
ECG mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco S&P Spin-Off ETF
$7.7M position · as of 2026-07-31
3.4%
Wasatch U.S. Select Fund
$571.0K position · as of 2026-06-30
3.3%
Wasatch Long/Short Alpha Fund
$1.0M position · as of 2026-06-30
2.7%
Invesco S&P SmallCap Industrials ETF
$4.6M position · as of 2026-05-31
2.6%
LONE PEAK VALUE FUND
$4.5M position · as of 2026-06-30
2.6%
Wasatch Small Cap Growth Fund
$30.4M position · as of 2026-06-30
2.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Jeffrey S. Thiede
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.9M
$8.7M
$1.8M
+63%
+59%
2024
$2.8M
$5.1M
$985.8K
+25%
+4%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $306.1K sold by insiders over 180 days, 268 funds added last quarter, $451.1K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ECG financials
Revenue growth
+31.5%
XBRL, annual
Net margin
5.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.3B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ECG
| FY Dec 2025 | $3.7B |
| FY Dec 2024 | $2.8B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $1.2B |
| Mar 2026 | $1.0B |
| Dec 2025 | $1.0B |
| Sep 2025 | $986.8M |
| Jun 2025 | $921.5M |
| Mar 2025 | $826.6M |
| Dec 2024 | $759.6M |
| Sep 2024 | $761.0M |
At each fiscal year end
Single quarter
Net margin, TTM
+6.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ECG
| FY Dec 2025 | +5.4% |
| FY Dec 2024 | +5.0% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | +6.8% |
| Mar 2026 | +5.6% |
| Dec 2025 | +5.5% |
| Sep 2025 | +5.8% |
| Jun 2025 | +5.7% |
| Mar 2025 | +4.4% |
| Dec 2024 | +4.5% |
| Sep 2024 | +5.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$250.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ECG
| FY Dec 2025 | $90.0M |
| FY Dec 2024 | $115.1M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $33.0M |
| Mar 2026 | $128.2M |
| Dec 2025 | $23.5M |
| Sep 2025 | $65.7M |
| Jun 2025 | $12.3M |
| Mar 2025 | -$11.4M |
| Dec 2024 | $66.9M |
| Sep 2024 | $60.9M |
At each fiscal year end
Single quarter
Debt to equity
0.36x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity ECG
| FY Dec 2025 | 0.45x |
| FY Dec 2024 | 0.70x |
| FY Dec 2023 | 0.38x |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.36x |
| Mar 2026 | 0.40x |
| Dec 2025 | 0.45x |
| Sep 2025 | 0.50x |
| Jun 2025 | 0.56x |
| Mar 2025 | 0.63x |
| Dec 2024 | 0.70x |
| Sep 2024 | 0.47x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
1.17x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ECG
| FY Dec 2025 | 0.56x |
| FY Dec 2024 | 0.55x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 1.17x |
| Mar 2026 | 1.06x |
| Dec 2025 | 0.56x |
| Sep 2025 | 0.66x |
| Jun 2025 | 0.67x |
| Mar 2025 | 0.51x |
| Dec 2024 | 0.55x |
| Sep 2024 | 0.90x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+39.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ECG
| FY Dec 2025 | +38.3% |
| FY Dec 2024 | +32.9% |
| FY Dec 2023 | +33.0% |
| FY Dec 2022 | n/a |
| Jun 2026 | +39.5% |
| Mar 2026 | +39.0% |
| Dec 2025 | +38.3% |
| Sep 2025 | +35.3% |
| Jun 2025 | +33.0% |
| Mar 2025 | +32.9% |
| Dec 2024 | +32.9% |
| Sep 2024 | +32.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+14.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ECG
| FY Dec 2025 | +13.4% |
| FY Dec 2024 | +12.3% |
| FY Dec 2023 | +13.0% |
| FY Dec 2022 | n/a |
| Jun 2026 | +14.4% |
| Mar 2026 | +13.9% |
| Dec 2025 | +13.4% |
| Sep 2025 | +12.5% |
| Jun 2025 | +11.2% |
| Mar 2025 | +11.2% |
| Dec 2024 | +12.3% |
| Sep 2024 | +11.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+26.2%
operating income after a 27.2% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital ECG
| FY Dec 2025 | +23.6% |
| FY Dec 2024 | +18.9% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | +26.2% |
| Mar 2026 | +24.8% |
| Dec 2025 | +23.6% |
| Sep 2025 | +21.7% |
| Jun 2025 | +20.3% |
| Mar 2025 | +19.3% |
| Dec 2024 | +18.9% |
| Sep 2024 | +21.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+33.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ECG
| FY Dec 2025 | +30.0% |
| FY Dec 2024 | +26.5% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | +33.2% |
| Mar 2026 | +31.4% |
| Dec 2025 | +30.0% |
| Sep 2025 | +29.3% |
| Jun 2025 | +25.7% |
| Mar 2025 | +24.9% |
| Dec 2024 | +26.5% |
| Sep 2024 | +27.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
19.75x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ECG
| FY Dec 2025 | 21.72x |
| FY Dec 2024 | 23.48x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 33.39x |
| Mar 2026 | 27.08x |
| Dec 2025 | 21.72x |
| Sep 2025 | 24.29x |
| Jun 2025 | 19.61x |
| Mar 2025 | 12.49x |
| Dec 2024 | 23.48x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$5.3B
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2024-09-30
Enterprise value ECG
| FY Dec 2025 | $4.6B |
| FY Dec 2024 | $3.6B |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | $8.7B |
| Mar 2026 | $6.3B |
| Dec 2025 | $4.6B |
| Sep 2025 | $4.7B |
| Jun 2025 | $3.5B |
| Mar 2025 | $2.2B |
| Dec 2024 | $3.6B |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield ECG
| FY Dec 2025 | +2.1% |
| FY Dec 2024 | +3.4% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | +3.0% |
| Mar 2026 | +3.8% |
| Dec 2025 | +2.1% |
| Sep 2025 | +3.1% |
| Jun 2025 | +4.0% |
| Mar 2025 | +4.8% |
| Dec 2024 | +3.4% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.37x
P/E over trailing EPS growth of 53%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing ECG
| FY Dec 2025 | 0.53x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | 0.63x |
| Mar 2026 | 0.58x |
| Dec 2025 | 0.53x |
| Sep 2025 | 1.00x |
| Jun 2025 | 1.05x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $3.7B | $2.8B | $2.9B | $2.7B |
| Gross profit | $454.1M | $339.5M | $321.9M | $276.0M |
| Operating income | $264.8M | $189.9M | $190.5M | $164.6M |
| Net income | $201.8M | $143.4M | $137.2M | $124.8M |
| EPS (diluted) | 3.95 | 2.81 | 2.69 | 2.45 |
| Operating cash flow | $156.8M | $163.4M | $171.3M | -$25.5M |
| Cash | n/a | n/a | $1.6M | n/a |
| Long-term debt | $266.5M | $280.6M | $168.5M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
ECG Stock Sonar score 6/7 axes
Find similar shapesCompareECG ranks highest on profitability (87th percentile) and growth (85th), and lowest on insider conviction (58th), among Construction peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ECG filings, in plain words
Are Everus Construction insiders buying or selling ECG?
In the 180 days to 2026-10-28, Everus Construction insiders were net sellers, a net $306.1K: $144.9K of purchases and $451.1K of sales reported on Form 4, by 1 buyer and 1 seller.
Are there planned insider sales of ECG?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $451.1K of stock; the latest, by Sanderson Paul R., was filed 2026-08-07.
Read the full summary
In the 180 days to 2026-10-28, Everus Construction insiders were net sellers of ECG, a net $306.1K across purchases and sales reported on Form 4 by 1 buyer and 1 seller. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $451.1K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
